- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
MFIC Corporation presented a significant discovery in their development program called Microfluidics Reaction Technology (MRT) during a poster presentation at the Nano Science and Technology Institute (NSTI) Nanotech 2007 Conference on Tuesday, May 22, 2007. MRT provides the next-generation in nanosuspension processes to help pharmaceutical and biotechnology companies develop and ultimately manufacture difficult to formulate drugs.
"The advent of MRT could potentially unlock uncounted drugs, vaccines and drug delivery systems that to date could not be formulated. It provides a critical advancement in the field of drug formulation and positions MFIC as a clear technology leader," said Bob Bruno, President & COO. "We anticipate introducing a line of equipment to facilitate the MRT process in the fourth quarter of this year, providing our customers with an additional effective and efficient solution for the creation of promising, new therapeutics."
MRT advances the manufacturing of nanosuspensions "bottom up" by chemical reactions or physical processes such as crystallization. It has been demonstrated for a variety of drugs using solvent and anti-solvent crystallization. This approach allows for a greater ability to control the growth rates of nanoparticles to produce uniform, optimally-sized nanoparticles in a more efficient, cost-effective manner. Conventional "top down" processes reduce particle sizes to the nano-level through a process of wet-milling, homogenization, micronization, and other techniques. MRT works by pumping liquid reactants through a coaxial feed system within a Microfluidizer® reaction chamber, which is based on impinging jet principals. The system provides precise control of the feed rate and mixing location.
"Through the use of MRT, MFIC engineers were able to produce nanosuspensions for several drugs, including two antibiotics, an antihistamine, an anticonvulsant and a non-steroidal anti-inflammatory," said Dr. Thomai Panagiotou, Vice President of Research and Development and the lead investigator and presenter of the study. "Importantly, MRT was demonstrated to be more effective in producing nanosuspensions than standard, particle size reducing methods," concluded Dr. Panagiotou.
The MRT technology and applications are outlined in the poster presented at the NSTI meeting. The poster will be accessible later this week on the Company's Web site at http://www.microfluidicscorp.com/ .
About MFIC Corporation
MFIC Corporation, through its Microfluidics Division, designs, manufactures and distributes patented and proprietary high performance Microfluidizer(R) materials processing equipment to the biotechnology, pharmaceutical, chemical, cosmetics/personal care, and food industries. MFIC applies its 20 years of high pressure processing experience to produce the most uniform and smallest liquid and suspended solid structures available, and has provided manufacturing systems for nanoparticle products for more than 15 years.
The Company is a leader in advanced materials processing equipment for laboratory, pilot scale and manufacturing applications, offering innovative technology and comprehensive solutions for nanoparticles and other materials processing and production. More than 3,000 systems are in use and afford significant competitive and economic advantages to MFIC equipment customers.
Forward Looking Statement:
Management believes that this release contains forward-looking statements that are subject to certain risks and uncertainties including statements relating to the Company’s plan to attain and/or increase operating profitability and/or to achieve net profitability. Such statements are based on management’s current expectations and are subject to a number of factors and uncertainties that could cause actual results achieved by the Company to differ materially from those described in the forward-looking statements. The Company cautions investors that there can be no assurance that the actual results or business conditions will not differ materially from those projected or suggested in such forward-looking statements as a result of various factors, including but not limited to the following risks and uncertainties: (i) whether the performance advantages of the Company’s Microfluidizer® materials processing equipment will be realized commercially or that a commercial market for the equipment will continue to develop, (ii) whether the performance advantages of the Company’s MMR and MRT nanoparticle production systems will be realized commercially, (iii) whether the Company will be able to increase its market penetration and market share, (iv) whether the timing of orders will significantly affect quarterly revenues and resulting net income results for particular quarters which may cause increased volatility in the Company’s stock price, and (v) whether the Company will have access to sufficient working capital through continued and improving cash flow from sales, and ongoing borrowing availability, the latter being subject to the Company’s ability to comply with the covenants and terms of its loan agreement with its senior lender.
For more information, please click here
Robert P. Bruno, President & COO
Jack M. Swig, Investor Relations
Copyright © Business Wire 2007If you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
Cooling graphene-based film close to pilot-scale production April 30th, 2016
Personal cooling units on the horizon April 29th, 2016
Exploring phosphorene, a promising new material April 29th, 2016
Researchers create a first frequency comb of time-bin entangled qubits: Discovery is a significant step toward multi-channel quantum communication and higher capacity quantum computers April 28th, 2016
Introducing the RE標ORK Bio-inspired Robotics Summit in Berlin April 27th, 2016